$GBLX
GB SCIENCES INC

2024 Q1 Form 10-Q Financial Statement

#000143774924003766 Filed on February 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $234.0K
YoY Change -42.55%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $369.9K $234.0K
YoY Change -30.16% -42.55%
Operating Profit -$369.9K -$234.0K
YoY Change -30.16% -42.55%
Interest Expense -$97.16K $38.27K
YoY Change 58.27% -7.72%
% of Operating Profit
Other Income/Expense, Net $0.00 $46.73K
YoY Change -100.0% -212.69%
Pretax Income -$467.1K -$187.3K
YoY Change -83.7% -58.27%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$476.1K -$187.3K
YoY Change -83.38% -58.27%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 406.1M 402.7M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.99K $17.46K
YoY Change -89.09% -93.63%
Cash & Equivalents $11.99K $17.46K
Short-Term Investments
Other Short-Term Assets $91.45K $129.7K
YoY Change -54.18% -18.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $103.4K $147.1K
YoY Change -66.58% -66.04%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $103.4K $147.1K
Total Long-Term Assets $0.00 $0.00
Total Assets $103.4K $147.1K
YoY Change -70.64% -94.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.140M $2.020M
YoY Change 7.95% 15.33%
Accrued Expenses $0.00 $75.63K
YoY Change -100.0% 99.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.437M $1.437M
YoY Change 2.95% 3.58%
Total Short-Term Liabilities $5.096M $4.919M
YoY Change 7.06% 11.9%
LONG-TERM LIABILITIES
Long-Term Debt $322.0K $75.00K
YoY Change 893.38%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $322.0K $75.00K
YoY Change 893.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.096M $4.919M
Total Long-Term Liabilities $322.0K $75.00K
Total Liabilities $5.418M $4.994M
YoY Change 13.82% 13.41%
SHAREHOLDERS EQUITY
Retained Earnings -$110.1M -$109.6M
YoY Change 1.25% 3.55%
Common Stock $40.72K $40.72K
YoY Change 6.64% 7.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.314M -$4.847M
YoY Change
Total Liabilities & Shareholders Equity $103.4K $147.1K
YoY Change -70.64% -94.73%

Cashflow Statement

Concept 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$476.1K -$187.3K
YoY Change -83.38% -58.27%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$252.5K -$205.4K
YoY Change 14.82% -48.57%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $85.00K
YoY Change
Cash From Investing Activities $0.00 $85.00K
YoY Change -6490.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 247.0K 33.34K
YoY Change 342.97% 95.89%
NET CHANGE
Cash From Operating Activities -252.5K -205.4K
Cash From Investing Activities 0.000 85.00K
Cash From Financing Activities 247.0K 33.34K
Net Change In Cash -5.470K -87.06K
YoY Change -96.67% -77.31%
FREE CASH FLOW
Cash From Operating Activities -$252.5K -$205.4K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$252.5K -$205.4K
YoY Change 14.82% -48.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2432492 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2390297 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
406071028
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
406071028
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
381872561
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
381872561
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55462
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-3733133
dei Entity Address Address Line1
EntityAddressAddressLine1
9205 W. Russell Road, Suite 240
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89148
dei City Area Code
CityAreaCode
866
dei Local Phone Number
LocalPhoneNumber
721-0297
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
406071028
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17459 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109912 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
129655 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
199592 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
147114 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
309504 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
42819 usd
CY2023Q4 us-gaap Assets
Assets
147114 usd
CY2023Q1 us-gaap Assets
Assets
352323 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
427391 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
346806 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
75628 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
75628 usd
CY2023Q4 gblx Notes Convertible Notes Payable And Line Of Credit Current
NotesConvertibleNotesPayableAndLineOfCreditCurrent
1437307 usd
CY2023Q1 gblx Notes Convertible Notes Payable And Line Of Credit Current
NotesConvertibleNotesPayableAndLineOfCreditCurrent
935000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
461077 usd
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
958455 usd
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
958455 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4919182 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4759706 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
75000 usd
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4994182 usd
CY2023Q1 us-gaap Liabilities
Liabilities
4759706 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
40721 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
38187 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
104712156 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
104259745 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109599945 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108705315 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4847068 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4407383 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
147114 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
352323 usd
CY2023Q4 us-gaap Revenues
Revenues
0 usd
CY2022Q4 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q4 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2022Q4 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q4 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q4 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
234007 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
407302 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1050621 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1142658 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-234007 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-407302 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1050621 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1142658 usd
CY2023Q4 us-gaap Interest Expense
InterestExpense
38269 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
41470 usd
us-gaap Interest Expense
InterestExpense
121815 usd
us-gaap Interest Expense
InterestExpense
117260 usd
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
85000 usd
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
320000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2023Q4 gblx Gain Loss On Impairment Of Capitalized Patent Costs
GainLossOnImpairmentOfCapitalizedPatentCosts
0 usd
CY2022Q4 gblx Gain Loss On Impairment Of Capitalized Patent Costs
GainLossOnImpairmentOfCapitalizedPatentCosts
0 usd
gblx Gain Loss On Impairment Of Capitalized Patent Costs
GainLossOnImpairmentOfCapitalizedPatentCosts
-42194 usd
gblx Gain Loss On Impairment Of Capitalized Patent Costs
GainLossOnImpairmentOfCapitalizedPatentCosts
0 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
46731 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-41470 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
155991 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-117260 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-187276 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-448772 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-894630 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1259918 usd
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-187276 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-448772 usd
us-gaap Net Income Loss
NetIncomeLoss
-894630 usd
us-gaap Net Income Loss
NetIncomeLoss
-1259918 usd
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
269218 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-187276 usd
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-448772 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1163848 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1259918 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
403172478
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
378912416
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
393637213
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
350397710
us-gaap Profit Loss
ProfitLoss
-894630 usd
us-gaap Profit Loss
ProfitLoss
-1259918 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
624 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
61660 usd
us-gaap Share Based Compensation
ShareBasedCompensation
219168 usd
us-gaap Share Based Compensation
ShareBasedCompensation
17333 usd
gblx Gain Loss On Collection Of Notes Receivable
GainLossOnCollectionOfNotesReceivable
320000 usd
gblx Gain Loss On Collection Of Notes Receivable
GainLossOnCollectionOfNotesReceivable
-0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
41230 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
45339 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
42194 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-69939 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
65252 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
37661 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-71827 usd
gblx Increase Decrease In Accrued Liabilities Excluding Interest Payable
IncreaseDecreaseInAccruedLiabilitiesExcludingInterestPayable
0 usd
gblx Increase Decrease In Accrued Liabilities Excluding Interest Payable
IncreaseDecreaseInAccruedLiabilitiesExcludingInterestPayable
28323 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
80584 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-62629 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-723230 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1306971 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
-0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
31650 usd
us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
320000 usd
us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
320000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31650 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
253529 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
75000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1625000 usd
gblx Payments For Brokerage Fees For Exercise Of Warrants
PaymentsForBrokerageFeesForExerciseOfWarrants
17752 usd
gblx Payments For Brokerage Fees For Exercise Of Warrants
PaymentsForBrokerageFeesForExerciseOfWarrants
211250 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
-0 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
34984 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
310777 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1378766 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-92453 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
40145 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
109912 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
233893 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17459 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
274038 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
134550 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
gblx Patent Filing And Drafting Costs Capitalized In Intangible Assets
PatentFilingAndDraftingCostsCapitalizedInIntangibleAssets
7700 usd
gblx Patent Filing And Drafting Costs Capitalized In Intangible Assets
PatentFilingAndDraftingCostsCapitalizedInIntangibleAssets
166639 usd
gblx Compensation Warrants Issued To Brokers In Private Placement
CompensationWarrantsIssuedToBrokersInPrivatePlacement
0 usd
gblx Compensation Warrants Issued To Brokers In Private Placement
CompensationWarrantsIssuedToBrokersInPrivatePlacement
147879 usd
CY2023Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
269218 usd
CY2022Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1193368 usd
CY2022Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26100 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4333 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-448772 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1611707 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4693126 usd
CY2023Q4 gblx Exercise Of Warrants For Stock Value
ExerciseOfWarrantsForStockValue
33334 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-187276 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4847068 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1782872 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1413750 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17333 usd
us-gaap Net Income Loss
NetIncomeLoss
-1259918 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1611707 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4407383 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
-0 usd
gblx Exercise Of Warrants For Stock Value
ExerciseOfWarrantsForStockValue
253529 usd
gblx Adjustments To Additional Paid In Capital Brokerage Fees On Exercise Of Warrants
AdjustmentsToAdditionalPaidInCapitalBrokerageFeesOnExerciseOfWarrants
-17752 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
219168 usd
gblx Adjustments To Additional Paid In Capital Warrant Reinstatement And Repricing
AdjustmentsToAdditionalPaidInCapitalWarrantReinstatementAndRepricing
269218 usd
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
269218 usd
us-gaap Net Income Loss
NetIncomeLoss
-894630 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4847068 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to valuation of beneficial conversion features in convertible debt, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets.  These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are <em style="font: inherit;">not</em> readily apparent from other sources. The actual results the Company experiences <em style="font: inherit;"> may </em>differ materially and adversely from these estimates.</p>
CY2023 gblx Debt Instrument Reclassification Of Debt To Convertible Notes Payable
DebtInstrumentReclassificationOfDebtToConvertibleNotesPayable
461077 usd
CY2023Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts
42194 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
624 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
61660 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
176512503
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
173786468
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109599945 usd
CY2023Q4 gblx Working Capital Deficit
WorkingCapitalDeficit
-4772068 usd
CY2023Q1 gblx Working Capital Deficit
WorkingCapitalDeficit
-4407383 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-723230 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1306971 usd
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1512307 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
-0 usd
CY2023Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
1512307 usd
gblx Class Of Warrant Or Right Exercises In Period
ClassOfWarrantOrRightExercisesInPeriod
25348467
gblx Class Of Warrant Or Right Exercises In Period Exercise Price
ClassOfWarrantOrRightExercisesInPeriodExercisePrice
0.01
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
253529 usd
gblx Brokerage Fees Exercise Of Warrants
BrokerageFeesExerciseOfWarrants
17752 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
122758677
gblx Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
23006492
gblx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0.01
gblx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
25348467
gblx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0.01
gblx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
10543084
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
109873618
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
23000000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
23000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2700000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.11
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
28883334
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.06
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
28883334
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.06
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
221650 usd

Files In Submission

Name View Source Status
gblx-20231231_pre.xml Edgar Link unprocessable
0001437749-24-003766-index-headers.html Edgar Link pending
0001437749-24-003766-index.html Edgar Link pending
0001437749-24-003766.txt Edgar Link pending
0001437749-24-003766-xbrl.zip Edgar Link pending
ex_624970.htm Edgar Link pending
ex_624971.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gblx-20231231.xsd Edgar Link pending
gblx-20231231_cal.xml Edgar Link unprocessable
gblx-20231231_lab.xml Edgar Link unprocessable
gblx-20231231_def.xml Edgar Link unprocessable
gblx20231231_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gblx20231231_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable